Alliance Global Partners Comments on Cresco Labs Q3 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Investment analysts at Alliance Global Partners raised their Q3 2025 EPS estimates for Cresco Labs in a report issued on Wednesday, March 12th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings per share of ($0.02) for the quarter, up from their prior estimate of ($0.03). The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Alliance Global Partners also issued estimates for Cresco Labs’ Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.09) EPS and FY2026 earnings at ($0.08) EPS.

Separately, Atb Cap Markets lowered shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $3.00.

Cresco Labs Price Performance

CRLBF opened at $0.75 on Monday. The company has a market capitalization of $364.25 million, a price-to-earnings ratio of -3.73 and a beta of 1.79. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80. Cresco Labs has a 12-month low of $0.70 and a 12-month high of $2.60. The business’s fifty day simple moving average is $0.89 and its 200-day simple moving average is $1.20.

Cresco Labs (OTCMKTS:CRLBF) last announced its quarterly earnings data on Friday, March 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The company had revenue of $176.00 million for the quarter, compared to analysts’ expectations of $172.10 million. Cresco Labs had a negative return on equity of 16.52% and a negative net margin of 9.15%.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.